Malignant ascites is a buildup of fluid in the abdomen caused by cancer. It develops when tumors spread to the lining of the abdominal cavity or block the lymphatic channels that normally drain fluid from that space. Unlike ascites caused by liver disease, which is far more common, malignant ascites signals advanced cancer and requires a different management approach.
Why Fluid Builds Up
Your abdominal cavity normally contains a small amount of fluid that lubricates the organs. Cancer disrupts the balance between fluid production and drainage through two main pathways. First, tumor deposits on the peritoneum (the membrane lining the abdomen) can block the tiny lymphatic vessels responsible for absorbing excess fluid. Second, cancer cells produce a protein called vascular endothelial growth factor, or VEGF, that makes blood vessel walls leakier than normal. This increased permeability lets protein-rich fluid seep out of blood vessels and pool in the abdominal cavity faster than the body can reabsorb it.
The combination of blocked drainage and increased leakage means fluid can accumulate rapidly, sometimes requiring drainage every few days.
Which Cancers Cause It
Malignant ascites is most common in people with ovarian, stomach, colon, pancreatic, liver, breast, lung, uterine, or bladder cancers. Ovarian cancer is the single most frequent cause, partly because the ovaries sit directly within the peritoneal cavity, giving cancer cells easy access to the abdominal lining. Gastrointestinal cancers (stomach, colon, pancreatic) collectively account for a large share as well, since they tend to spread along the peritoneal surface as they advance.
Symptoms and What It Feels Like
The hallmark symptom is progressive abdominal swelling that develops over days to weeks. At first you might notice your clothes fitting tighter or a sense of bloating that doesn’t resolve. As more fluid collects, the abdomen becomes visibly distended and firm.
Beyond the swelling itself, the pressure from liters of trapped fluid creates a cascade of secondary symptoms. Many people experience early satiety, feeling full after eating only a small amount, because the fluid compresses the stomach. Shortness of breath is common as the diaphragm gets pushed upward by the expanding abdomen, and some patients develop fluid around the lungs (pleural effusion) at the same time. Weight loss from the underlying cancer can occur simultaneously with weight gain from the fluid, which can be disorienting. Abdominal discomfort, constipation, and loss of appetite round out the typical picture.
On physical exam, doctors look for flank dullness when tapping on the abdomen, a “shifting dullness” that moves when you change position, and a visible fluid wave across the belly.
How It’s Diagnosed
Imaging, usually an ultrasound or CT scan, confirms that fluid is present. But identifying the fluid as malignant rather than caused by liver disease or infection requires a procedure called paracentesis, where a needle is inserted into the abdomen to draw off a sample.
The key lab test on that fluid is the serum-ascites albumin gradient, or SAAG. A SAAG of 1.1 g/dL or higher points strongly toward liver-related ascites from portal hypertension, with 97% sensitivity. A SAAG below 1.1 g/dL, combined with a total protein level of 2.5 g/dL or higher in the fluid, is the pattern typical of malignant ascites. Cancer cells produce protein-rich fluid, which distinguishes it from the watery fluid seen in liver disease.
Cytology, examining the fluid under a microscope for cancer cells, is the definitive confirmation. It has 100% specificity, meaning a positive result is virtually certain to be correct. However, its sensitivity is only about 60%, so cancer cells are missed in roughly 4 out of 10 cases on a single sample. Repeat sampling or additional testing may be needed when suspicion is high but the first cytology comes back negative.
Drainage With Paracentesis
The most immediate treatment is large-volume paracentesis: inserting a needle or catheter to drain off the excess fluid. This provides rapid symptom relief, often within hours. Unlike liver-related ascites, where removing more than 5 liters in one session requires intravenous albumin to prevent circulatory problems, patients with malignant ascites can generally be drained to dryness in a single session over about 8 hours without albumin replacement. This is often done as a day procedure.
The limitation is that the fluid almost always comes back. Many patients need repeated paracentesis every one to three weeks, which means frequent clinic visits, needle sticks, and time spent in a medical setting.
Indwelling Catheters for Home Drainage
For people who need frequent drainage, an indwelling peritoneal catheter offers an alternative. This is a small, tunneled tube placed through the abdominal wall that stays in place long-term, allowing you or a caregiver to drain fluid at home on a regular schedule.
Most patients drain daily or every other day, removing up to about 2,000 mL per session. Studies consistently report improvement in abdominal swelling, discomfort, appetite, and constipation. The biggest advantage is eliminating repeated trips to the hospital for paracentesis.
Complications are relatively uncommon but worth knowing about. Catheter malfunction, including blockage or poor drainage, occurs in about 5.7% of cases. Infection at the catheter site or within the abdomen (peritonitis) happens in about 5.4%, and the risk rises noticeably after the catheter has been in place for more than 12 weeks. Fluid leaking around the catheter site affects roughly 4% of patients. Tunneled catheters, which pass through a short tunnel under the skin before entering the abdomen, have lower infection and dislodgement rates than non-tunneled versions.
Other Treatment Approaches
Because malignant ascites is driven by the underlying cancer, systemic cancer treatment (chemotherapy, targeted therapy, or immunotherapy depending on the tumor type) can slow fluid reaccumulation when the cancer responds. In ovarian cancer especially, effective chemotherapy often dramatically reduces ascites.
Diuretics, the water pills that work well for liver-related ascites, are generally less effective for malignant ascites because the fluid accumulation isn’t driven by the same salt-and-water retention mechanism. Some patients with mixed causes (cancer plus liver disease) do get partial benefit.
For refractory cases where paracentesis and catheters aren’t sufficient or feasible, a peritoneovenous shunt is a surgical option. This device channels ascitic fluid from the abdominal cavity back into the bloodstream through a one-way valve. It’s reserved for patients who aren’t responding to other treatments and have a life expectancy of at least three months. The procedure works in most patients, but complications are common: only about 18.6% of shunts remain functional at two years, and risks include blood clotting disorders, infection, and shunt blockage. About 9% of patients develop a serious clotting complication called disseminated intravascular coagulation after placement.
Prognosis and Survival
Malignant ascites generally indicates advanced disease, and overall prognosis depends heavily on the type of cancer and how well it responds to treatment. For many solid tumors like pancreatic or stomach cancer, median survival after the onset of malignant ascites is measured in weeks to a few months.
Ovarian cancer is a notable exception. A study of 277 women with metastatic ovarian cancer and malignant ascites found a mean overall survival of about 69 months, or nearly six years. Nearly 10% of these patients survived more than 10 years, with an average survival of over 15 years in that long-survivor group. Low-grade serous carcinoma was the subtype most associated with long survival, though even some patients with high-grade serous or clear cell carcinoma achieved long-term survival. These numbers reflect ovarian cancer’s relatively strong response to chemotherapy compared with many other abdominal cancers.
The wide range in outcomes underscores that a diagnosis of malignant ascites, while serious, carries very different implications depending on the primary cancer type and its treatment options.